Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

panadiplon

Known as: 3-(5-cyclopropyl-1,2,4-oxadiazol 3-yl)-5-(1-methylethyl)imidazo(1,5-a)quinoxalin-4(5H)-one 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
  • Alisa Opar
  • Nature Reviews Drug Discovery
  • 2012
  • Corpus ID: 37258153
A new €32 million project aimed at understanding drug-induced liver injury is the latest of several collaborative efforts that… Expand
2005
2005
Ethanol's ability to enhance GABA neurotransmission via GABA(A) receptors has been implicated as an important mechanism… Expand
Highly Cited
2004
Highly Cited
2004
  • L. Yu
  • Pharmaceutical Research
  • 2004
  • Corpus ID: 5910972
AbstractPurpose. To develop an integrated absorption model for estimating the fraction of dose absorbed and determining the… Expand
2002
2002
5-Ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5] imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide) (RWJ-51204… Expand
2001
2001
The pentobarbital-like discriminative stimulus effects of the benzodiazepine receptor partial agonist panadiplon were assessed in… Expand
1999
1999
The benzodiazepine receptor ligand U-78875 [3-(5-cyclopro pyl-1,2, 4-oxadiazol-3-yl)-5-(1-methylethyl)imidazol(1, 5-a)quinoxalin… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
1998
1998
The quinoxalinone anxiolytic, panadiplon, was dropped from clinical development due to unexpected hepatic toxicity in human… Expand
1996
1996
The quinoxalinone anxiolytic, panadiplon, produces hepatic metabolic inhibition (mitochondrial impairment), microvesicular… Expand
1995
1995
The non-benzodiazepine anxiolytic, panadiplon, was discontinued from clinical development due to evidence of hepatic toxicity in… Expand
1994
1994
SummaryAnxiety disorders are common psychiatric problems and the cause of considerable morbidity. Following the demise of the… Expand
  • table I